UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

68.97EUR
30 Jan 2015
Change (% chg)

€-0.28 (-0.40%)
Prev Close
€69.25
Open
€69.61
Day's High
€69.86
Day's Low
€68.79
Volume
240,947
Avg. Vol
272,547
52-wk High
€75.62
52-wk Low
€50.11

UCB.BR

Chart for UCB.BR

About

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.60
Market Cap(Mil.): €13,469.52
Shares Outstanding(Mil.): 194.51
Dividend: 0.78
Yield (%): 1.13

Financials

  UCB.BR Industry Sector
P/E (TTM): 51.96 39.97 40.64
EPS (TTM): 1.33 -- --
ROI: 2.91 18.85 18.12
ROE: 5.35 19.60 18.97
Search Stocks

BRIEF-UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

* UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

21 Jan 2015

BRIEF-UCB, Neuropore to develop Parkison's treatment

* Neuropore Therapies Inc and UCB enter into world-wide collaboration and agreement

16 Jan 2015

BRIEF-UCB, Advent International and Avista Capital Partners terminate acquisition of Kremers Urban

* UCB, Advent International and Avista Capital Partners mutually agree to terminate acquisition agreement for Kremers Urban

16 Dec 2014

BRIEF-UCB announces partnership with Daiichi Sankyo in Japan

* Announces partnership with Daiichi Sankyo for co-commercialization of Lacosamide in Japan

28 Nov 2014

BRIEF-UCB Phase 3 clinical study on VIMPAT meets primary efficacy endpoint

* Phase 3 clinical study evaluating VIMPAT (lacosamide) meets its primary efficacy endpoint

28 Oct 2014

UCB revenue up 6 pct in Jan-Sept, keeps outlook

BRUSSELS, Oct 24 - Belgian pharmaceutical company UCB reported a 6 percent rise in revenue in the first nine months of 2014 as improved sales of its leading three drugs easily made up for erosion of a former blockbuster and maintained its full-year outlook.

24 Oct 2014

BRIEF-UCB expects core earnings per share in the range of 1.90-2.05 euro

* First nine month revenue up 6 pct to 2.6 billion euro (up 8 pct at constant exchange rates)

24 Oct 2014

Deals of the day- Mergers and acquisitions

Oct 23 - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Thursday:

23 Oct 2014

RPT-Market Chatter- Corporate finance press digest - Oct 23

Oct 23 - The following corporate finance-related stories were reported by media:

23 Oct 2014

Market Chatter- Corporate finance press digest - Oct 23

Oct 23 - The following corporate finance-related stories were reported by media:

22 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$10.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks